Genomatica today announced that major nylon intermediates — including hexamethylenediamine, caprolactam and adipic acid (HMD, CPL and ADA) — are the focus of its third publicly disclosed development program.
The biotechnology company is developing complete process technologies for the biobased production of these intermediates, which it will then license to major firms in the nylon value chain. These three chemicals, with a total market of over $18 billion per year, are used primarily in the production of nylon 6 and nylon 6,6, also referred to as the polyamides PA 6 and PA 6,6.
Genomatica’s nylon intermediates program follows commercialization and licensing of its GENO BDO process, and strong progress with its butadiene program, which has gained over $100 million in industry support, with Versalis and Braskem as anchor partners.
As with its butadiene program, Genomatica is inviting leaders in the nylon value chain to join as development partners for its nylon intermediates program.
Development partners have the opportunity to engage throughout the program, influence priorities and gain early access to the resulting process technology. Genomatica says that such access can provide important time-to-market and competitive advantage to program sponsors.